Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

but still less than what’s been seen with competitor Eli Lilly’s Zepbound. In a 72-week study, a 7.2-milligram dose of Wegovy led patients with obesity to lose 18.7% of their weight ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight-loss medications. MORE: In Kensington, outreach workers give out food, clothing and ...

Zepbound (tirzepatide ... resulted in significant and sustained weight loss. The study, which had support from the drug’s manufacturer, found that tirzepatide resulted in a mean total body ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...